Medicines Co (MDCO) Shares Rose While Corvex Management LP Trimmed by $13.51 Million Its Position

June 17, 2018 - By reb123z

The Medicines Company (NASDAQ:MDCO) LogoInvestors sentiment decreased to 1.02 in Q1 2018. Its down 0.23, from 1.25 in 2017Q4. It turned negative, as 30 investors sold MDCO shares while 51 reduced holdings. 25 funds opened positions while 58 raised stakes. 91.05 million shares or 1.80% more from 89.44 million shares in 2017Q4 were reported. Nelson Van Denburg And Campbell Wealth Mngmt Grp Inc Ltd Com invested in 4,630 shares. Profund Advisors Limited Liability Corporation has 14,146 shares. Raymond James & holds 0% or 7,818 shares. Geode Limited Co reported 640,566 shares. Millennium stated it has 7,141 shares. 7,101 are owned by Old West Invest Mgmt Limited Liability Co. Pointstate Capital LP reported 3.71 million shares. Creative Planning has 0.01% invested in The Medicines Company (NASDAQ:MDCO) for 90,517 shares. 2.52 million were reported by Putnam Investments Limited Liability Com. Comerica Bank reported 0.01% of its portfolio in The Medicines Company (NASDAQ:MDCO). Alliancebernstein LP owns 107,846 shares or 0% of their US portfolio. Bain Pub Equity Management Lc accumulated 56,504 shares. Rhenman Prtn Asset Mgmt stated it has 0.41% in The Medicines Company (NASDAQ:MDCO). Dekabank Deutsche Girozentrale accumulated 0.01% or 39,900 shares. Credit Suisse Ag holds 0% of its portfolio in The Medicines Company (NASDAQ:MDCO) for 78,766 shares.

Since January 16, 2018, it had 0 insider buys, and 3 sales for $1.06 million activity. $241,950 worth of The Medicines Company (NASDAQ:MDCO) shares were sold by CROUSE WILLIAM. On Tuesday, January 16 the insider KESSLER ARMIN M sold $574,200.

Keith Meister decreased its stake in Medicines Co (MDCO) by 17.51% based on its latest 2018Q1 regulatory filing with the SEC. Corvex Management Lp sold 422,054 shares as the company’s stock rose 4.51% while stock markets declined. The hedge fund run by Keith Meister held 1.99M shares of the major pharmaceuticals company at the end of 2018Q1, valued at $65.51 million, down from 2.41M at the end of the previous reported quarter. Corvex Management Lp who had been investing in Medicines Co for a number of months, seems to be less bullish one the $2.72 billion market cap company. The stock increased 0.57% or $0.21 during the last trading session, reaching $36.9. About 709,936 shares traded. The Medicines Company (NASDAQ:MDCO) has declined 16.45% since June 17, 2017 and is downtrending. It has underperformed by 29.02% the S&P500.

Analysts await The Medicines Company (NASDAQ:MDCO) to report earnings on August, 8. They expect $-1.00 EPS, up 81.88 % or $4.52 from last year’s $-5.52 per share. After $-0.80 actual EPS reported by The Medicines Company for the previous quarter, Wall Street now forecasts 25.00 % negative EPS growth.

More recent The Medicines Company (NASDAQ:MDCO) news were published by: Seekingalpha.com which released: “Rounds Report: Melinta Rallied While Novavax Experienced Significant Insider Purchases” on June 06, 2018. Also Seekingalpha.com published the news titled: “Rounds Report: Melinta Rallied While The FDA Approved OsteoDetect” on May 26, 2018. Seekingalpha.com‘s news article titled: “Premarket analyst action – healthcare” with publication date: June 07, 2018 was also an interesting one.

The Medicines Company (NASDAQ:MDCO) Ratings Coverage

Among 4 analysts covering Medicines Co (NASDAQ:MDCO), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Medicines Co had 6 analyst reports since January 15, 2018 according to SRatingsIntel. The stock of The Medicines Company (NASDAQ:MDCO) earned “Buy” rating by Oppenheimer on Thursday, March 22. Oppenheimer maintained The Medicines Company (NASDAQ:MDCO) rating on Monday, January 15. Oppenheimer has “Buy” rating and $50.0 target. The firm has “Buy” rating given on Monday, January 22 by Citigroup. The stock of The Medicines Company (NASDAQ:MDCO) earned “Buy” rating by FBR Capital on Wednesday, June 6. Oppenheimer maintained The Medicines Company (NASDAQ:MDCO) rating on Thursday, February 22. Oppenheimer has “Hold” rating and $50.0 target.

The Medicines Company (NASDAQ:MDCO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: